Name | Value |
---|---|
Revenues | 0.0M |
Cost of Revenue | 0.0M |
Gross Profit | 0.0M |
Operating Expense | 17.4M |
Operating I/L | -17.4M |
Other Income/Expense | -2.2M |
Interest Income | 0.0M |
Pretax | -19.6M |
Income Tax Expense | 2.2M |
Net Income/Loss | -21.8M |
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system, respiratory, and other disorders. The company's lead programs include SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation in patients with major depressive disorders; SLS-005, a protein stabilizer for amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for Parkinson's disease. Additionally, Seelos has preclinical programs targeting PD, chronic inflammation in asthma, narcolepsy, and post-operative pain management.